Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 6c, beats revenue
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $240.07 --0%
Revenue Growth %: +7.1%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +7.1%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
- Sysco raises mid-term targets, unveils $500M AI efficiency program
- Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
